MediWound (MDWD) to Release Quarterly Earnings on Thursday

Key Points

• MediWound (NASDAQ:MDWD) is expected to announce its Q2 2025 earnings on August 13, with analysts predicting a loss of ($0.55) per share and revenue of $5.68 million.
• The company recently reported a loss of ($0.07) per share for the last quarter, exceeding consensus estimates, but revenue was below expectations at $3.96 million.
• Market analysts remain divided, with one rating the stock as a sell while others maintain buy ratings, resulting in a consensus rating of "Moderate Buy" with an average price target of $32.25.

MediWound (NASDAQ:MDWD - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.55) per share and revenue of $5.68 million for the quarter. MediWound has set its FY 2025 guidance at EPS.

MediWound (NASDAQ:MDWD - Get Free Report) last posted its quarterly earnings results on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.58. MediWound had a negative net margin of 110.45% and a negative return on equity of 74.12%. The business had revenue of $3.96 million for the quarter, compared to analysts' expectations of $5.20 million. During the same period in the prior year, the company posted ($1.05) EPS. On average, analysts expect MediWound to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MediWound Trading Down 0.8%

Shares of NASDAQ:MDWD traded down $0.15 on Friday, reaching $18.63. 35,170 shares of the company were exchanged, compared to its average volume of 66,947. MediWound has a 1-year low of $14.14 and a 1-year high of $22.50. The company has a 50-day moving average of $19.94 and a 200-day moving average of $18.65. The firm has a market cap of $201.39 million, a price-to-earnings ratio of -8.91 and a beta of 0.21.

Institutional Trading of MediWound

An institutional investor recently raised its position in MediWound stock. Rhumbline Advisers raised its position in MediWound Ltd. (NASDAQ:MDWD - Free Report) by 4.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,316 shares of the biopharmaceutical company's stock after acquiring an additional 481 shares during the quarter. Rhumbline Advisers owned 0.10% of MediWound worth $176,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 46.83% of the company's stock.

Wall Street Analyst Weigh In

MDWD has been the topic of several recent analyst reports. Wall Street Zen lowered shares of MediWound from a "hold" rating to a "sell" rating in a report on Friday, July 18th. HC Wainwright set a $31.00 price objective on shares of MediWound and gave the stock a "buy" rating in a report on Thursday, May 22nd. Oppenheimer began coverage on shares of MediWound in a research report on Monday, June 2nd. They set an "outperform" rating and a $34.00 target price for the company. Finally, Alliance Global Partners began coverage on shares of MediWound in a research report on Friday, May 2nd. They set a "buy" rating and a $25.00 target price for the company. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $32.25.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.